Partner Content Partner Content Neurostimulation Devices Market will achieve 15% CAGR up to ... Neurostimulation Devices Market to reach $19bn by 2025
News BMS says it will set Cobenfy's UK price the same as the US Bristol Myers Squibb's price tag for schizophrenia drug Cobenfy in the UK is a manifestation of Trump's most favoured nation drug pricing policy.
Sales & Marketing FH25: Individual centric investing with Steve Seuntjens In a new FH25 podcast episode, Deep Dive editor Eloise McLennan speaks with Steve Seuntjens, Partner at PHS Capital.
